Skip to main content
Erschienen in: Journal of Neurology 12/2019

20.09.2019 | Original Communication

Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QuIC

verfasst von: Samir Abu-Rumeileh, Simone Baiardi, Barbara Polischi, Angela Mammana, Alessia Franceschini, Alison Green, Sabina Capellari, Piero Parchi

Erschienen in: Journal of Neurology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Prion real-time quaking-induced conversion (RT-QuIC) is emerging as the most potent assay for the in vivo diagnosis of Creutzfeldt–Jakob disease (CJD), but its full application, especially as a screening test, is limited by suboptimal substrate availability, reagent costs, and incomplete assay standardization. Therefore, the search for the most informative cerebrospinal fluid (CSF) surrogate biomarker is still of primary importance. We compared the diagnostic accuracy of CSF protein 14-3-3, measured with both western blot (WB) and enzyme-linked immunosorbent assay (ELISA), total (t)-tau and neurofilament light chain protein (NfL) alone or in combination with RT-QuIC in 212 subjects with rapidly progressive dementia in which we reached a highly probable clinical diagnosis at follow-up or a definite neuropathological diagnosis. T-tau performed best as surrogate CSF biomarker for the diagnosis of CJD (91.3% sensitivity and 78.9% specificity). The 14-3-3 ELISA assay demonstrated a slightly higher diagnostic value compared to the WB analysis (76.9% vs. 72.2%), but both methods performed worse than the t-tau assay. NfL was the most sensitive biomarker for all sCJD subtypes (> 95%), including those with low values of t-tau or 14-3-3, but showed the lowest specificity (43.1%). When ELISA-based biomarkers were adopted as screening tests followed by RT-QuIC, t-tau correctly excluded a higher number of non-CJD cases compared to NfL and 14-3-3 ELISA. Our study showed that among the CSF surrogate biomarkers of potential application for the clinical diagnosis of CJD, t-tau performs best either alone or as screening test followed by RT-QuIC as a second-level confirmatory test.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Baiardi S, Rossi M, Capellari S, Parchi P (2019) Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol 29:278–300CrossRef Baiardi S, Rossi M, Capellari S, Parchi P (2019) Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol 29:278–300CrossRef
2.
Zurück zum Zitat Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233CrossRef Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233CrossRef
3.
Zurück zum Zitat Parchi P, Strammiello R, Notari S et al (2009) Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 118:659–671CrossRef Parchi P, Strammiello R, Notari S et al (2009) Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 118:659–671CrossRef
4.
Zurück zum Zitat Parchi P, de Boni L, Saverioni D et al (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529CrossRef Parchi P, de Boni L, Saverioni D et al (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124:517–529CrossRef
5.
Zurück zum Zitat Baiardi S, Capellari S, Bartoletti Stella A, Parchi P (2018) Unusual clinical presentations challenging the early clinical diagnosis of Creutzfeldt–Jakob disease. J Alzheimers Dis 64:1051–1065CrossRef Baiardi S, Capellari S, Bartoletti Stella A, Parchi P (2018) Unusual clinical presentations challenging the early clinical diagnosis of Creutzfeldt–Jakob disease. J Alzheimers Dis 64:1051–1065CrossRef
6.
Zurück zum Zitat Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Brain 132:2659–2668CrossRef Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Brain 132:2659–2668CrossRef
7.
Zurück zum Zitat Chohan G, Pennington C, Mackenzie JM et al (2010) The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt–Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 81:1243–1248CrossRef Chohan G, Pennington C, Mackenzie JM et al (2010) The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt–Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 81:1243–1248CrossRef
8.
Zurück zum Zitat Hamlin C, Puoti G, Berri S et al (2012) A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt–Jakob disease. Neurology 79:547–552CrossRef Hamlin C, Puoti G, Berri S et al (2012) A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt–Jakob disease. Neurology 79:547–552CrossRef
9.
Zurück zum Zitat Lattanzio F, Abu-Rumeileh S, Franceschini A et al (2017) Prion-specific and surrogate CSF biomarkers in Creutzfeldt–Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels. Acta Neuropathol 133:559–578CrossRef Lattanzio F, Abu-Rumeileh S, Franceschini A et al (2017) Prion-specific and surrogate CSF biomarkers in Creutzfeldt–Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels. Acta Neuropathol 133:559–578CrossRef
10.
Zurück zum Zitat Rudge P, Hyare H, Green A, Collinge J, Mead S (2018) Imaging and CSF analyses effectively distinguish CJD from its mimics. J Neurol Neurosurg Psychiatry 89:461–466CrossRef Rudge P, Hyare H, Green A, Collinge J, Mead S (2018) Imaging and CSF analyses effectively distinguish CJD from its mimics. J Neurol Neurosurg Psychiatry 89:461–466CrossRef
11.
Zurück zum Zitat McGuire LI, Peden AH, Orrú CD et al (2012) Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt–Jakob disease. Ann Neurol 72:278–285CrossRef McGuire LI, Peden AH, Orrú CD et al (2012) Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt–Jakob disease. Ann Neurol 72:278–285CrossRef
12.
Zurück zum Zitat Groveman BR, Orrú CD, Hughson AG et al (2016) Extended and direct evaluation of RT-QuIC assays for Creutzfeldt–Jakob disease diagnosis. Ann Clin Transl Neurol 4:139–144CrossRef Groveman BR, Orrú CD, Hughson AG et al (2016) Extended and direct evaluation of RT-QuIC assays for Creutzfeldt–Jakob disease diagnosis. Ann Clin Transl Neurol 4:139–144CrossRef
13.
Zurück zum Zitat Foutz A, Appleby BS, Hamlin C et al (2017) Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol 81:79–92CrossRef Foutz A, Appleby BS, Hamlin C et al (2017) Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol 81:79–92CrossRef
14.
Zurück zum Zitat Franceschini A, Baiardi S, Hughson AG et al (2017) High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci Rep 7:10655CrossRef Franceschini A, Baiardi S, Hughson AG et al (2017) High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci Rep 7:10655CrossRef
15.
Zurück zum Zitat Schmitz M, Ebert E, Stoeck K et al (2016) Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt–Jakob disease diagnostic. Mol Neurobiol 53:2189–2199CrossRef Schmitz M, Ebert E, Stoeck K et al (2016) Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt–Jakob disease diagnostic. Mol Neurobiol 53:2189–2199CrossRef
16.
Zurück zum Zitat Leitão MJ, Baldeiras I, Almeida MR et al (2016) Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience 322:398–407CrossRef Leitão MJ, Baldeiras I, Almeida MR et al (2016) Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience 322:398–407CrossRef
17.
Zurück zum Zitat Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt–Jakob disease. Sci Rep 6:38737CrossRef Steinacker P, Blennow K, Halbgebauer S et al (2016) Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt–Jakob disease. Sci Rep 6:38737CrossRef
18.
Zurück zum Zitat Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther 10:3CrossRef Abu-Rumeileh S, Capellari S, Stanzani-Maserati M et al (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther 10:3CrossRef
19.
Zurück zum Zitat Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement 14:751–763CrossRef Zerr I, Schmitz M, Karch A et al (2018) Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement 14:751–763CrossRef
20.
Zurück zum Zitat Kanata E, Golanska E, Villar-Piqué A et al (2019) Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt–Jakob disease. J Clin Neurosci 60:124–127CrossRef Kanata E, Golanska E, Villar-Piqué A et al (2019) Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt–Jakob disease. J Clin Neurosci 60:124–127CrossRef
21.
Zurück zum Zitat Grau-Rivera O, Gelpi E, Nos C et al (2015) Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis 15:350–360CrossRef Grau-Rivera O, Gelpi E, Nos C et al (2015) Clinicopathological correlations and concomitant pathologies in rapidly progressive dementia: a brain bank series. Neurodegener Dis 15:350–360CrossRef
22.
Zurück zum Zitat Geschwind MD, Murray K (2018) Differential diagnosis with other rapid progressive dementias in human prion diseases. Handb Clin Neurol 153:371–397CrossRef Geschwind MD, Murray K (2018) Differential diagnosis with other rapid progressive dementias in human prion diseases. Handb Clin Neurol 153:371–397CrossRef
23.
Zurück zum Zitat Zerr I, Hermann P (2018) Diagnostic challenges in rapidly progressive dementia. Expert Rev Neurother 18:761–772CrossRef Zerr I, Hermann P (2018) Diagnostic challenges in rapidly progressive dementia. Expert Rev Neurother 18:761–772CrossRef
24.
Zurück zum Zitat Jansen C, Parchi P, Capellari S et al (2012) Human prion diseases in the Netherlands (1998–2009): clinical, genetic and molecular aspects. PLoS ONE 7:e36333CrossRef Jansen C, Parchi P, Capellari S et al (2012) Human prion diseases in the Netherlands (1998–2009): clinical, genetic and molecular aspects. PLoS ONE 7:e36333CrossRef
26.
Zurück zum Zitat McGuire LI, Poleggi A, Poggiolini I et al (2016) Cerebrospinal fluid real-time quaking-induced conversion is a robust and reliable test for sporadic Creutzfeldt–Jakob disease: an international study. Ann Neurol 80:160–165CrossRef McGuire LI, Poleggi A, Poggiolini I et al (2016) Cerebrospinal fluid real-time quaking-induced conversion is a robust and reliable test for sporadic Creutzfeldt–Jakob disease: an international study. Ann Neurol 80:160–165CrossRef
27.
Zurück zum Zitat Otto M, Wiltfang J, Cepek L et al (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 58:192–197CrossRef Otto M, Wiltfang J, Cepek L et al (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease. Neurology 58:192–197CrossRef
28.
Zurück zum Zitat Skillbäck T, Rosén C, Asztely F et al (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt–Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 71:476–483CrossRef Skillbäck T, Rosén C, Asztely F et al (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt–Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 71:476–483CrossRef
29.
Zurück zum Zitat Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90:870–881CrossRef Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90:870–881CrossRef
30.
Zurück zum Zitat Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol 24:1326–e77CrossRef Kovacs GG, Andreasson U, Liman V et al (2017) Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol 24:1326–e77CrossRef
Metadaten
Titel
Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QuIC
verfasst von
Samir Abu-Rumeileh
Simone Baiardi
Barbara Polischi
Angela Mammana
Alessia Franceschini
Alison Green
Sabina Capellari
Piero Parchi
Publikationsdatum
20.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2019
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-019-09537-0

Weitere Artikel der Ausgabe 12/2019

Journal of Neurology 12/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.